CJC-1295 never reached drug approval

The early answer: hormone rises left benefits unproved

Did CJC-1295 make the adults in early tests healthier? Adults' growth hormone rose in the tests, alongside another growth protein, without proof of lasting health benefits ^[4][5].

The drug copies 29 amino acids, tiny joined parts that form proteins. Four changes slow how quickly the body breaks the drug down.

DAC names the form that fastens to a protein blood carries. That form keeps working for roughly 5-8 days ^[4][7].

Larger amounts in the studies caused larger hormone rises. The rises didn't establish better health or easier daily living.

CJC-1295 never won approval from the FDA or another major drug authority. Development ended before large trials could test treatment over years.

2024: FDA pharmacy advisers raised concerns about the immune system fighting the drug ^[1]. Your immune system normally defends your body against illness.

The advisers opposed adding the drug to a list of ingredients pharmacies may use to make prescriptions. A clinic's offer leaves two questions: may the pharmacy make the prescription, and has treatment been tested for your health problem at your age and with the medicines you take?

WADA, the group setting drug rules for sport, bans use throughout the year. Higher hormone readings don't remove the ban or settle the risks.

Research users also describe effects outside formal studies. Those accounts lack a comparison group to help show what caused a change.

DAC keeps the drug in blood for days

CJC-1295 copies 29 amino acids, the small joined parts that form proteins. Scientists replaced parts numbered 2, 8, 15, and 27, counting from one end.

Those numbers mark the places changed in the copied hormone. The point for you is that the changes slow breakdown.

CJC-1295 DAC also attaches to albumin, a protein that blood already carries. The attachment lets the drug remain in blood for days.

If you follow albumin already present in blood, roughly half clears over 19 days. Your body keeps replacing albumin, so you aren't losing half your blood's total supply.

That figure describes albumin, not the length of the drug's action. Drug tests measured the drug's own time in blood separately.

No-DAC names the form that cannot attach firmly to albumin. Modified GRF and Mod GRF are other names for no-DAC.

No-DAC has the same four changes, but the body clears no-DAC within hours. People discussing research use and some labels confuse the forms ^[7].

DAC's days of raised hormones can mean more swelling and other unwanted effects. An account of hours of action concerns no-DAC; an account of days concerns DAC, so knowing the form is essential before you can understand what someone reports.

Men kept their usual hormone bursts despite higher readings

CJC-1295 makes the gland produce and send out growth hormone. That hormone raises insulin-like growth factor 1, a protein involved in growing new cells and repairing damage ^[1].

Knowing the protein helps growth doesn't establish better health at your age. A blood change and a health benefit are separate findings.

CJC-1295 leaves the body's ways of slowing hormone release working. Those limits don't establish safety for treatment that lasts years.

In healthy men, CJC-1295 didn't change the size or timing of hormone bursts ^[5]. The gland continued its regular rhythm of growth-hormone release.

DAC keeps acting for days; no-DAC acts for hours. Hormone levels between bursts can rise while the bursts themselves stay unchanged.

An earlier study compared drugs with and without the blood-protein attachment in rats ^[7]. Over 2 hours, the attached drug caused 4-fold greater growth-hormone exposure.

The researchers added the hormone readings over time to compare the rats' exposure. They could still detect CJC-1295 in rat blood beyond 72 hours.

These rat findings help explain why the attachment lengthens action. The findings don't tell you whether the drug would help an older person stay well, or what harm might follow after months or years of treatment.

Adult studies mainly found blood changes

Human tests of CJC-1295 measured hormone levels and time in blood. They didn't prove that the adults felt better or lived healthier lives.

Healthy adults' hormone levels rose after study shots. The adults were ages 21-61; researchers put the shots under the skin ^[4].

The shots contained 30 or 60 micrograms for each kilogram the person weighed. A microgram weighs just one millionth as much as a gram; a kilogram weighs slightly more than two pounds.

Growth hormone rose 2- to 10-fold for 6 or more days. Blood tests measured several times the adults' earlier hormone levels.

Repeated CJC-1295 shots also kept the liver's growth protein raised. The protein stayed above its starting level for up to 28 days.

Young men kept the same rhythm of hormone bursts. Men ages 20-40 received CJC-1295 in a study shot under the skin ^[5].

The study shot contained 60 or 90 micrograms for each kilogram the person weighed. Doctors watched healthy study participants, so those figures cannot tell you what is safe for someone of your age who may also have illnesses and take medicines that change treatment risks.

The average growth-hormone reading rose 46%, based on readings taken over time. The liver's growth protein rose 45% one week later.

Hormone levels between bursts also rose in these men. The bursts kept their earlier size and timing.

Blood proteins changed in 11 healthy young men receiving CJC-1295. Some proteins carrying fats and thyroid hormone, which controls how quickly your body uses energy, fell ^[3].

Tests found more pieces of albumin and more immune-system proteins. The changes didn't show whether the men benefited or suffered harm.

Finding those proteins doesn't by itself show damage or the body fighting the drug. These blood changes might help researchers detect raised growth-hormone activity.

Mice unable to make the hormone-release message grew normally with CJC-1295. The mice lacked inherited instructions for making that message ^[6].

Daily treatment restored normal weight and length; less frequent treatment did less. The mice's growth glands also showed signs of making more hormone.

Tests found CJC-1295 in material taken during a sports investigation. That finding identified the drug, without testing anyone's health benefit ^[2].

2025: a review covered possible medical uses of these drugs. The review also discussed questions that treatment studies hadn't answered ^[1].

Personal accounts describe changes that studies have not checked

People using CJC-1295 for research describe changes in sleep and health. These accounts come from research users themselves; no formal study has checked the claims against changes in people who didn't receive the drug.

People report both welcome changes and discomfort. Their accounts describe what they noticed, without proving what caused the change.

• Sleep seemed deeper, sometimes within the first week: People often mention sleep before other changes.

Growth hormone normally rises during deep sleep; that fact doesn't prove the drug improved their sleep.

• Legs felt less sore after hard exercise: Some people felt readier for their next workout.

Sleep and becoming used to training can also reduce soreness.

• Fat around the waist seemed to shrink: Reports often place the change in weeks three to six.

Many people also changed meals and exercise, making the drug's part unclear.

• Muscles looked firmer while weight was being lost: People usually describe small changes that took time.

Steady exercise and eating habits could also explain the appearance changes.

• Hands became puffy or tingled: Reports describe more trouble with the form that acts for days.

Higher growth hormone can make the body hold salt and water, causing pressure on nerves.

• A shot caused flushing or a lightheaded feeling: Some accounts concern no-DAC, the form cleared within hours.

People often say the feeling faded within minutes.

• Blood sugar increased or insulin worked less well: Insulin helps keep blood sugar down.

These reports raise concerns if you already have blood-sugar trouble or use the drug for a long time.

The research also leaves serious risks unanswered. A welcome change cannot settle those risks.

• CJC-1295 never gained approval for treating people. The published human tests were small and brief ^[4].

Those tests cannot tell you what happens during years of use.

• 2024: FDA advisers worried the immune system might fight CJC-1295. The October review raised that safety concern ^[1].

The advisers opposed allowing the drug onto the ingredient list for pharmacy-made prescriptions.

• Raised growth proteins leave a cancer question. Large studies link lasting high levels of the liver's growth protein with some cancers ^[1].

Those findings don't tell you how much cancer risk CJC-1295 adds, including if cancer has affected you or your family.

• Growth hormone can cause swelling and raise blood sugar. The kidneys can hold more salt and water under its influence ^[4].

Fluid buildup puts pressure on nerves; higher hormone levels can also make insulin less able to keep blood sugar down.

• The treatment-testing program stopped before approval. Phase 2 means early tests of possible benefit after initial safety testing ^[7].

Accounts of the stopped development also mention a patient's death. The death report doesn't establish which trial the patient joined, whether the patient received the drug, or whether the death had any link to the drug.

• CJC-1295 form names are sometimes mixed up. Research discussions and labels can confuse DAC and no-DAC ^[7].

DAC's days of action and no-DAC's hours of action can bring different unwanted effects.

• Sport rules ban CJC-1295 throughout the year. WADA's rule appears under Section S2, its heading for these hormone drugs ^[2].

Drug tests can detect use, and competitors face penalties.

Some people say their swelling eased after a few weeks. That relief isn't proof that continued use is safe for you.

Longer action gives unwanted effects more time

CJC-1295 can keep growth-hormone levels higher well after a brief burst. Early studies found that blood change, without proving safe long use.

Swelling and changes in blood sugar may therefore last longer. Raised growth proteins also leave questions about cancer unanswered.

The stopped development left the drug without an approved treatment use. No lasting health benefit has been proved for healthy older people.

Sermorelin clears more quickly and once treated children lacking growth hormone. That history cannot tell you whether treatment helps at your age.

The comparison of treatment findings sets out those differences. How you feel and function needs evidence beyond a higher blood-test reading.